<p>CervoMed（纳斯达克代码：CRVO - 获取免费报告）的股票在周二由 D. Boral Capital 在给投资者的一份报告中重申了 “买入” 评级，Benzinga 报道。他们目前对该股票的目标价为 31.00 美元。D. Boral Capital 的目标价意味着该股票相较于之前的收盘价有 236.23% 的潜在上涨空间。</p>
<p>其他股票研究分析师最近也发布了关于该公司的研究报告。Zacks Research 在 10 月 13 日的研究报告中将 CervoMed 的评级从 “持有” 下调至 “强烈卖出”。HC Wainwright 在 11 月 5 日的报告中将 CervoMed 的评级从 “中性” 上调至 “买入”，并将该公司的目标价从 11.00 美元上调至 25.00 美元。Chardan Capital 在 8 月 11 日的研究报告中重申了 “买入” 评级，并对 CervoMed 的股票设定了 15.00 美元的目标价。Roth Capital 在 10 月 17 日的研究报告中对 CervoMed 的股票设定了 20.00 美元的目标价，并给予该公司 “买入” 评级。最后，Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 CervoMed 的 “卖出（d-）” 评级。一位投资分析师给予该股票 “强烈买入” 评级，七位分析师给予 “买入” 评级，三位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 21.86 美元。</p>
<p><strong>阅读我们关于 CervoMed 的最新研究报告</strong></p>
<h2>CervoMed 价格表现</h2>
<p>CRVO 股票在周二开盘价为 9.22 美元。CervoMed 的年低为 1.80 美元，年高为 16.94 美元。该股票的市值为 8531 万美元，市盈率为-3.53，贝塔值为-0.89。该公司有 50 日简单移动平均线为 7.97 美元，200 日简单移动平均线为 8.14 美元。</p>
<p>CervoMed（纳斯达克代码：CRVO - 获取免费报告）最近在 11 月 7 日发布了季度财报。该公司报告每股收益为（0.84 美元），低于市场共识预期的（0.68 美元）16 美分。CervoMed 的净利润率为-290.72%，股本回报率为-59.15%。该公司季度收入为 32 万美元，而分析师预期为 143 万美元。研究分析师平均预计 CervoMed 在当前财年将发布-1.88 的每股收益。</p>
<h2>CervoMed 的内部交易</h2>
<p>在其他消息中，首席执行官 John J. Alam 在 11 月 17 日的交易中购买了 10,807 股公司的股票。该股票的平均购买价格为每股 8.46 美元，总价值为 91,427.22 美元。交易完成后，首席执行官直接持有公司股票 1,484,078 股，价值约为 12,555,299.88 美元。这代表其持股比例增加了 0.73%。此次收购在向证券交易委员会的法律文件中披露，该文件可在 SEC 网站上获取。此外，董事 Sylvie Gregoire 在 11 月 17 日的交易中购买了 10,807 股公司的股票。该股票的平均购买成本为每股 8.46 美元，总交易额为 91,427.22 美元。收购后，该董事在公司持有 12,500 股，价值约为 105,750 美元。此次交易使其持股比例增加了 638.33%。该购买的 SEC 文件提供了更多信息。在过去 90 天内，内部人士购买了 92,000 股公司股票，价值 737,723 美元。内部人士持有公司股票的比例为 35.40%。</p>
<h2>对 CervoMed 的对冲基金看法</h2>
<p>几家对冲基金和其他机构投资者最近修改了对 CRVO 的持股。Rhumbline Advisers 在第一季度将其在 CervoMed 的股份增加了 35.5%。Rhumbline Advisers 目前持有 5,830 股公司股票，价值 53,000 美元，此前在上个季度购买了 1,526 股。GSA Capital Partners LLP 在第三季度购买了 CervoMed 的新股份，价值约 91,000 美元。HighTower Advisors LLC 在第一季度购买了 CervoMed 的新股份，价值约 104,000 美元。Marshall Wace LLP 在第二季度购买了 CervoMed 的新股份，价值约 76,000 美元。最后，纽约梅隆银行在第一季度购买了 CervoMed 的新股份，价值约 110,000 美元。25.15% 的股票由机构投资者持有。</p>
<h2>CervoMed 公司简介</h2>
<p>（获取免费报告）</p>
<p>CervoMed Inc 是一家生物技术公司，专注于开发和商业化针对与年龄相关的神经疾病的治疗。其主要药物候选者是 neflamapimod，这是一种口服小分子药物，能够穿透大脑，用于治疗路易体痴呆（DLB）、阿尔茨海默病、额颞叶痴呆和缺血性中风恢复。</p>
<h2>特色文章</h2>
<ul>
<li>我们更看好的五只股票比 CervoMed 更好</li>
<li>黄金交叉股票：模式、示例和图表</li>
<li>这些是第三季度报告周期中最热门的升级</li>
<li>股票市场升级：它们是什么？</li>
<li>化石股票悄然上涨——内部人士刚刚进行了大额押注</li>
<li>做空 - 利弊分析</li>
<li>为什么像 IBIT 这样的比特币 ETF 可能会在 2026 年激增</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWTw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 CervoMed 1,000 美元吗？</h2>
<p>在你考虑 CervoMed 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐现在购买，以便在更广泛的市场注意到之前……而 CervoMed 并不在名单上。</p>
<p>虽然 CervoMed 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

CRVO

<p>D. Boral Capital 重申了对 CervoMed 的 “买入” 评级，目标价为 31.00 美元，表示潜在上涨幅度为 236.23%。其他分析师的评级则不一，Zacks Research 将其评级下调至 “强烈卖出”，而 HC Wainwright 则上调至 “买入”。该股票开盘价为 9.22 美元，市值为 8531 万美元。内部人士和对冲基金积极购买该股票，内部人士持有公司 35.40% 的股份</p>

<p>CervoMed (NASDAQ:CRVO - Get Free Report)'s stock had its &#34;buy&#34; rating reaffirmed by D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They presently have a $31.00 price objective on the stock. D. Boral Capital's price target would indicate a potential upside of 236.23% from the stock's previous close.</p>
<div class="lb-trans"><p>CervoMed（纳斯达克代码：CRVO - 获取免费报告）的股票在周二由 D. Boral Capital 在给投资者的一份报告中重申了 “买入” 评级，Benzinga 报道。他们目前对该股票的目标价为 31.00 美元。D. Boral Capital 的目标价意味着该股票相较于之前的收盘价有 236.23% 的潜在上涨空间。</p>
</div><p>Other equities research analysts also recently issued research reports about the company. Zacks Research downgraded CervoMed from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research report on Monday, October 13th. HC Wainwright raised CervoMed from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and raised their price objective for the company from $11.00 to $25.00 in a report on Wednesday, November 5th. Chardan Capital reaffirmed a &#34;buy&#34; rating and issued a $15.00 target price on shares of CervoMed in a research note on Monday, August 11th. Roth Capital set a $20.00 price target on shares of CervoMed and gave the company a &#34;buy&#34; rating in a research report on Friday, October 17th. Finally, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of CervoMed in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $21.86.</p>
<div class="lb-trans"><p>其他股票研究分析师最近也发布了关于该公司的研究报告。Zacks Research 在 10 月 13 日的研究报告中将 CervoMed 的评级从 “持有” 下调至 “强烈卖出”。HC Wainwright 在 11 月 5 日的报告中将 CervoMed 的评级从 “中性” 上调至 “买入”，并将该公司的目标价从 11.00 美元上调至 25.00 美元。Chardan Capital 在 8 月 11 日的研究报告中重申了 “买入” 评级，并对 CervoMed 的股票设定了 15.00 美元的目标价。Roth Capital 在 10 月 17 日的研究报告中对 CervoMed 的股票设定了 20.00 美元的目标价，并给予该公司 “买入” 评级。最后，Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 CervoMed 的 “卖出（d-）” 评级。一位投资分析师给予该股票 “强烈买入” 评级，七位分析师给予 “买入” 评级，三位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 21.86 美元。</p>
</div><p><strong>Read Our Latest Research Report on CervoMed</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 CervoMed 的最新研究报告</strong></p>
</div><h2>CervoMed Price Performance</h2>
<div class="lb-trans"><h2>CervoMed 价格表现</h2>
</div><p>CRVO stock opened at $9.22 on Tuesday. CervoMed has a one year low of $1.80 and a one year high of $16.94. The stock has a market cap of $85.31 million, a PE ratio of -3.53 and a beta of -0.89. The firm has a 50 day simple moving average of $7.97 and a two-hundred day simple moving average of $8.14.</p>
<div class="lb-trans"><p>CRVO 股票在周二开盘价为 9.22 美元。CervoMed 的年低为 1.80 美元，年高为 16.94 美元。该股票的市值为 8531 万美元，市盈率为-3.53，贝塔值为-0.89。该公司有 50 日简单移动平均线为 7.97 美元，200 日简单移动平均线为 8.14 美元。</p>
</div><p>CervoMed (NASDAQ:CRVO - Get Free Report) last posted its quarterly earnings data on Friday, November 7th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.16). CervoMed had a negative net margin of 290.72% and a negative return on equity of 59.15%. The company had revenue of $0.32 million for the quarter, compared to analysts' expectations of $1.43 million. On average, research analysts expect that CervoMed will post -1.88 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>CervoMed（纳斯达克代码：CRVO - 获取免费报告）最近在 11 月 7 日发布了季度财报。该公司报告每股收益为（0.84 美元），低于市场共识预期的（0.68 美元）16 美分。CervoMed 的净利润率为-290.72%，股本回报率为-59.15%。该公司季度收入为 32 万美元，而分析师预期为 143 万美元。研究分析师平均预计 CervoMed 在当前财年将发布-1.88 的每股收益。</p>
</div><h2>Insider Transactions at CervoMed</h2>
<div class="lb-trans"><h2>CervoMed 的内部交易</h2>
</div><p>In other news, CEO John J. Alam purchased 10,807 shares of the company's stock in a transaction on Monday, November 17th. The stock was acquired at an average price of $8.46 per share, with a total value of $91,427.22. Following the transaction, the chief executive officer directly owned 1,484,078 shares of the company's stock, valued at approximately $12,555,299.88. This represents a 0.73% increase in their position. The acquisition was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, Director Sylvie Gregoire purchased 10,807 shares of the business's stock in a transaction on Monday, November 17th. The stock was purchased at an average cost of $8.46 per share, for a total transaction of $91,427.22. Following the acquisition, the director owned 12,500 shares in the company, valued at approximately $105,750. The trade was a 638.33% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have bought 92,000 shares of company stock worth $737,723. Insiders own 35.40% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席执行官 John J. Alam 在 11 月 17 日的交易中购买了 10,807 股公司的股票。该股票的平均购买价格为每股 8.46 美元，总价值为 91,427.22 美元。交易完成后，首席执行官直接持有公司股票 1,484,078 股，价值约为 12,555,299.88 美元。这代表其持股比例增加了 0.73%。此次收购在向证券交易委员会的法律文件中披露，该文件可在 SEC 网站上获取。此外，董事 Sylvie Gregoire 在 11 月 17 日的交易中购买了 10,807 股公司的股票。该股票的平均购买成本为每股 8.46 美元，总交易额为 91,427.22 美元。收购后，该董事在公司持有 12,500 股，价值约为 105,750 美元。此次交易使其持股比例增加了 638.33%。该购买的 SEC 文件提供了更多信息。在过去 90 天内，内部人士购买了 92,000 股公司股票，价值 737,723 美元。内部人士持有公司股票的比例为 35.40%。</p>
</div><h2>Hedge Funds Weigh In On CervoMed</h2>
<div class="lb-trans"><h2>对 CervoMed 的对冲基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of CRVO. Rhumbline Advisers grew its stake in shares of CervoMed by 35.5% in the first quarter. Rhumbline Advisers now owns 5,830 shares of the company's stock worth $53,000 after purchasing an additional 1,526 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in CervoMed in the 3rd quarter worth approximately $91,000. HighTower Advisors LLC bought a new stake in shares of CervoMed in the 1st quarter worth approximately $104,000. Marshall Wace LLP purchased a new position in shares of CervoMed during the second quarter valued at approximately $76,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of CervoMed during the first quarter valued at approximately $110,000. 25.15% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近修改了对 CRVO 的持股。Rhumbline Advisers 在第一季度将其在 CervoMed 的股份增加了 35.5%。Rhumbline Advisers 目前持有 5,830 股公司股票，价值 53,000 美元，此前在上个季度购买了 1,526 股。GSA Capital Partners LLP 在第三季度购买了 CervoMed 的新股份，价值约 91,000 美元。HighTower Advisors LLC 在第一季度购买了 CervoMed 的新股份，价值约 104,000 美元。Marshall Wace LLP 在第二季度购买了 CervoMed 的新股份，价值约 76,000 美元。最后，纽约梅隆银行在第一季度购买了 CervoMed 的新股份，价值约 110,000 美元。25.15% 的股票由机构投资者持有。</p>
</div><h2>CervoMed Company Profile</h2>
<div class="lb-trans"><h2>CervoMed 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.</p>
<div class="lb-trans"><p>CervoMed Inc 是一家生物技术公司，专注于开发和商业化针对与年龄相关的神经疾病的治疗。其主要药物候选者是 neflamapimod，这是一种口服小分子药物，能够穿透大脑，用于治疗路易体痴呆（DLB）、阿尔茨海默病、额颞叶痴呆和缺血性中风恢复。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than CervoMed</li>
<li>Golden Cross Stocks: Pattern, Examples and Charts</li>
<li>These Are the Hottest Upgrades From the Q3 Reporting Cycle</li>
<li>Stock Market Upgrades: What Are They?</li>
<li>Fossil Stock Is Quietly Surging—Insiders Just Made Big Bets</li>
<li>Short Selling - The Pros and Cons</li>
<li>Why Bitcoin ETFs Like IBIT May Be Set to Surge in 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 CervoMed 更好</li>
<li>黄金交叉股票：模式、示例和图表</li>
<li>这些是第三季度报告周期中最热门的升级</li>
<li>股票市场升级：它们是什么？</li>
<li>化石股票悄然上涨——内部人士刚刚进行了大额押注</li>
<li>做空 - 利弊分析</li>
<li>为什么像 IBIT 这样的比特币 ETF 可能会在 2026 年激增</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWTw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=CRVO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CervoMed Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 CervoMed 1,000 美元吗？</h2>
</div><p>Before you consider CervoMed, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 CervoMed 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CervoMed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐现在购买，以便在更广泛的市场注意到之前……而 CervoMed 并不在名单上。</p>
</div><p>While CervoMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CervoMed 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

CervoMed 的买入评级在 D. Boral Capital 得到了重申